a public good project by the
Synthesis
Company
of California

© 2026

Xiaoyan Ma | doi.page

0 works0 citations0 h-index

Xiaoyan Ma

Shanxi Medical University(CN)Shanghai East Hospital(CN)Guizhou Institute of Technology(CN)Shanxi Academy of Medical Sciences(CN)

Publications by Year

Research Areas

Dialysis and Renal Disease Management, Cancer-related molecular mechanisms research, RNA modifications and cancer, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations

Most-Cited Works

→ Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state(2019)300 cited
→ Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy(2020)123 cited
→ Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib(2020)102 cited
→ Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis(2022)87 cited
→ An Upstream Open Reading Frame in Phosphatase and Tensin Homolog Encodes a Circuit Breaker of Lactate Metabolism(2021)87 cited
→ Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury(2017)80 cited

→ Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients: a double-center prospective investigation(2015)74 cited

→ Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer(2021)71 cited

→ Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation(2019)67 cited

→ Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization(2023)66 cited